Compare Allstate Corp (ALL) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs AstraZeneca plc — how do they compare? Allstate Corp trades at $256.66 (market cap $66.31B), while AstraZeneca plc trades at $158.47 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 3.7× Allstate Corp's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| ALL | AZN | |
|---|---|---|
Market Cap | $66.31B | $248.14B |
Sector | Financials | Health |
52-Week High | $275.11 | $209.48 |
52-Week Low | $190.00 | $147.06 |
Enterprise Value | $74.96B | $275.41B |
Dividend Yield | 1.65% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $256.62, down 4.84% over 24 hours, but maintains a bullish technical signal with strong fundamental performance. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. Recent news highlights institutional buying and positive analyst coverage, though some caution exists on sustainability.
The outlook remains positive with a consensus price target of $266.47, offering potential upside. Key risks include sustainability of underwriting margins and macroeconomic sensitivity. Earnings momentum and valuation metrics support a favorable investment case, but investors should monitor competitive pressures and catastrophe loss trends.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
